AR100680A1 - ANTI-DR5 ANTIBODIES AND MOLECULES THAT INCLUDE DR5 JOINT DOMAINS OF THE SAME - Google Patents

ANTI-DR5 ANTIBODIES AND MOLECULES THAT INCLUDE DR5 JOINT DOMAINS OF THE SAME

Info

Publication number
AR100680A1
AR100680A1 ARP150101706A ARP150101706A AR100680A1 AR 100680 A1 AR100680 A1 AR 100680A1 AR P150101706 A ARP150101706 A AR P150101706A AR P150101706 A ARP150101706 A AR P150101706A AR 100680 A1 AR100680 A1 AR 100680A1
Authority
AR
Argentina
Prior art keywords
molecules
antibodies
binding
same
molecule
Prior art date
Application number
ARP150101706A
Other languages
Spanish (es)
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of AR100680A1 publication Critical patent/AR100680A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente se dirige al mAb 1 y mAb 2 del anticuerpo anti-DR5, y a versiones humanizadas y quiméricas de tales anticuerpos. Adicionalmente a moléculas de unión de DR5 que comprenden fragmentos de tales moléculas, y a moléculas biespecíficas que incluyen diacuerpos, BiTEs, anticuerpos biespecíficos de protuberancias / agujeros, etc., que; comprenden: (i) tales fragmentos de unión de DR5 y (ii) un dominio capaz de unirse a un epítopo de una molécula presente sobre la superficie de una célula efectora. Reivindicación 31: La molécula de unión de DR-5 anti-humano de conformidad con cualquiera de las reivindicaciones 1 - 30, caracterizada porque la molécula se utiliza en el tratamiento de cáncer.This is directed to mAb 1 and mAb 2 of the anti-DR5 antibody, and to humanized and chimeric versions of such antibodies. In addition to DR5 binding molecules comprising fragments of such molecules, and to bispecific molecules that include diabodies, BiTEs, bispecific antibodies of bumps / holes, etc., which; they comprise: (i) such DR5 binding fragments and (ii) a domain capable of binding to an epitope of a molecule present on the surface of an effector cell. Claim 31: The anti-human DR-5 binding molecule according to any one of claims 1-30, characterized in that the molecule is used in the treatment of cancer.

ARP150101706A 2015-01-26 2015-05-29 ANTI-DR5 ANTIBODIES AND MOLECULES THAT INCLUDE DR5 JOINT DOMAINS OF THE SAME AR100680A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562107786P 2015-01-26 2015-01-26

Publications (1)

Publication Number Publication Date
AR100680A1 true AR100680A1 (en) 2016-10-26

Family

ID=56544107

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101706A AR100680A1 (en) 2015-01-26 2015-05-29 ANTI-DR5 ANTIBODIES AND MOLECULES THAT INCLUDE DR5 JOINT DOMAINS OF THE SAME

Country Status (3)

Country Link
AR (1) AR100680A1 (en)
TW (1) TW201627322A (en)
WO (1) WO2016122701A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240023449A (en) 2017-02-08 2024-02-21 드래곤플라이 쎄라퓨틱스, 인크. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
US11884732B2 (en) 2017-02-20 2024-01-30 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
MX2019009943A (en) * 2017-02-20 2019-12-19 Dragonfly Therapeutics Inc Proteins binding gd2, nkg2d and cd16.
AU2018271872A1 (en) * 2017-05-23 2019-12-12 Dragonfly Therapeutics, Inc. A protein binding NKG2D, CD16 and ROR1 or ROR2
AU2018271930A1 (en) * 2017-05-23 2019-12-12 Dragonfly Therapeutics, Inc. A protein binding NKG2D, CD16 and a tumor-associated antigen
MX2019013995A (en) * 2017-05-23 2020-07-29 Dragonfly Therapeutics Inc A protein binding nkg2d, cd16 and a tumor-associated antigen.
EP3668893A4 (en) * 2017-08-16 2021-08-04 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16, and egfr, hla-e ccr4, or pd-l1
US10774139B2 (en) * 2017-11-10 2020-09-15 Ngm Biopharmaceuticals, Inc. ANGPTL8-binding agents and methods of use thereof
CN109836500A (en) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 It is a kind of to target the single-chain antibody of DR5, Chimeric antigen receptor T cell and its preparation method and application
CN109957020A (en) * 2017-12-25 2019-07-02 深圳宾德生物技术有限公司 It is a kind of to target the single-chain antibody of DR5, Chimeric antigen receptor T cell and its preparation method and application
CN109957024A (en) * 2017-12-25 2019-07-02 深圳宾德生物技术有限公司 It is a kind of to target the single-chain antibody of DR5, Chimeric antigen receptor T cell and its preparation method and application
WO2019127215A1 (en) * 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
MX2020008336A (en) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor.
EP3749347A4 (en) * 2018-02-08 2021-11-03 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
EP3790585A4 (en) * 2018-05-07 2022-05-11 Dragonfly Therapeutics, Inc. A protein binding nkg2d, cd16 and a tumor-associated antigen
US20230210901A1 (en) * 2020-04-23 2023-07-06 Baylor College Of Medicine Overcoming the tumor microenvironment for cell therapy by targeting myeloid derived suppressor cells through a trail-r2 specific receptor
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2024083021A1 (en) * 2022-10-20 2024-04-25 北京三诺佳邑生物技术有限责任公司 Antibody combination specifically binding to trail or fasl, and bispecific antibody

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003135075A (en) * 2001-11-05 2003-05-13 Research Association For Biotechnology NEW FULL-LENGTH cDNA
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20090297530A1 (en) * 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
WO2012002723A2 (en) * 2010-06-29 2012-01-05 성균관대학교산학협력단 Transparent conductive film, method for manufacturing same, and transparent electrode and device using same
US20140242077A1 (en) * 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response

Also Published As

Publication number Publication date
TW201627322A (en) 2016-08-01
WO2016122701A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
AR100680A1 (en) ANTI-DR5 ANTIBODIES AND MOLECULES THAT INCLUDE DR5 JOINT DOMAINS OF THE SAME
CO2017012553A2 (en) Lag-3 binding molecules
CY1124723T1 (en) PD-1 BINDING MOLECULES AND METHODS OF USING THEM
CL2021003535A1 (en) Anti-cd33 antibodies and methods to use them. (application divisional 3095-2019)
CL2019001926A1 (en) Anti-tigit antibodies and antigen-binding fragments; pharmaceutical composition comprising them; polynenucleotide encoding said antibody; vector comprising them, host cell; method of producing said antibody or antigen-binding fragment thereof; and use in the treatment of cancer. (Divisional Application 310-2017).
PE20191208A1 (en) ANTI-CD73 ANTIBODIES AND USES OF THEM
CO2019012210A2 (en) Anti-trem2 antibodies and methods of using them
CY1124771T1 (en) ANTI-SORTILINE ANTIBODIES AND METHODS OF USING THEM
CL2021001686A1 (en) Single Domain Antibody-Based Chimeric Antigen Receptors and Methods of Using Them (Divisional Application No. 201800378)
AR110676A1 (en) TREATMENT OF CANCER USING CHEMERIC ANTIGENS RECEPTORS
PH12018501554A1 (en) Ror1 antibody compositions and related methods
PE20190970A1 (en) ANTI-CD40 ANTIBODIES AND THEIR USES
CO2018011195A2 (en) Compositions comprising a coformulation of anti-pd-l1 and anti-ctla-4 antibodies
PE20180950A1 (en) BISPECIFIC ANTIBODIES SPECIFIC TO A CO-STIMULATING TNF RECEIVER
PE20181054A1 (en) HUMANIZED ANTI-CD19 ANTIBODIES AND METHODS OF USE
EA202092417A1 (en) CHIMERIC RECEPTORS TO DLL3 AND METHODS OF THEIR APPLICATION
EA201791270A1 (en) MODIFIED APRIL-BINDING ANTIBODIES
MX2018008934A (en) Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same.
EA201690447A1 (en) BISPECIFIC MONOVALENT DIATELS, WHICH ARE CAPABLE OF CONNECTING WITH gpA33 AND CD3, AND THEIR APPLICATION
PE20190737A1 (en) ANTI-CD27 ANTIBODIES
EA201990894A1 (en) ANTI-PD-1 / ANTI-HER2 HETERODIMERIC BASPECIFIC ANTIBODY WITH NATURAL ANTIBODY STRUCTURE AND METHOD FOR ITS PRODUCTION
CL2018001238A1 (en) Specific binding molecules for asct2 and their uses
CL2017000912A1 (en) Antibodies that bind to ccr6 and its uses
EA202190183A1 (en) ANTIBODIES TO SIGLEC-5 AND METHODS OF THEIR APPLICATION
PE20190633A1 (en) ANTI-GM-CSF ANTIBODIES AND USES OF THE SAME

Legal Events

Date Code Title Description
FB Suspension of granting procedure